Ibrutinib

伊布替尼

Report date: 2026/04/30 20:00:20
NMEFirst In Class

Base Information

Drug NameIbrutinib
Drug Alias Name艾卢替尼IbrutinibumImuburubika依鲁替尼伊鲁替尼 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaSolid tumours +[53] 
Global Approved IndicationsLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, Mantle-CellLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2013/11/13
Country/TerritoryCzechiaBelgiumCanada +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPharmacyclics Llc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative MedicineJanssen-Cilag International NvCatalent Pharma Solutions +[21] 
Inactive CompaniesDana-Farber Cancer InstituteNorthwestern University Feinberg School Of MedicineJanssen, Lp +[9] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Skin MelanomaSolid tumours +[27] 
Inactive IndicationsCentral Nervous System LymphomaRichter's SyndromeFood Hypersensitivity +[26] 

Other Information

ATC CodeL01EL01
Related LinksWikipediaDrugBankKEGG